Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25435787 | 0.87 | TSHR (0.54) | TSHRTDP1MEN1LMNACYP3A4 | |
| SCHEMBL37351 | 0.87 | TSHR (0.54) | TSHRTDP1MEN1LMNACYP3A4 | |
| Ammonia Solution, Strong SCHEMBL9998248 | 0.85 | TSHR (0.52) | TSHRTDP1MEN1LMNACYP3A4 | |
| SCHEMBL13133074 | 0.80 | TSHR (0.48) | TSHRTDP1MEN1LMNACYP3A4 | |
| Ethylene Glycol SCHEMBL14991179 | 0.80 | TSHR (0.48) | TSHRTDP1MEN1LMNACYP3A4 | |
| SCHEMBL30690962 | 0.79 | ALDH1A1 (0.40) | TSHRTDP1LMNACYP3A4ALDH1A1 | |
| SCHEMBL18924829 | 0.79 | MAPT (0.46) | TSHRTDP1MEN1LMNACYP3A4 | |
| SCHEMBL3115072 | 0.79 | — | — | |
| SCHEMBL8275261 | 0.78 | TSHR (0.46) | TSHRTDP1MEN1LMNACYP3A4 | |
| SCHEMBL17194018 | 0.78 | TSHR (0.52) | TSHRTDP1MEN1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164506-B | Dinucleotide compounds and prodrugs thereof | 正大天晴药业集团股份有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-113166190-B | Oligonucleotides and prodrugs | 正大天晴药业集团股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| CN-113164506-A | Dinucleotide compounds and prodrugs thereof | 正大天晴药业集团股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113166190-A | Oligonucleotides and prodrugs | 正大天晴药业集团股份有限公司 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020114495-A1 | DINUCLEOTIDE COMPOUND AND PRODRUG THEREOF | 正大天晴药业集团股份有限公司 | 2020-06-11 | — | — | WO | disclosed |
| WO-2016145103-A1 | AZA-PYRIDONE COMPOUNDS AND USES THEREOF | ALIOS BIOPHARMA, INC. (US) | 2016-09-15 | — | — | WO | disclosed |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | MEIJI SEIKA KAISHA (JP) | 2016-06-02 | — | — | US | disclosed |
| US-20160060287-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS, INC. | 2016-03-03 | — | — | US | disclosed |
| US-9260375-B2 | Metallo-β-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2016-02-16 | — | — | US | disclosed |
| US-20140323554-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | SPRING BANK PHARMACEUTICALS, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8076303-B2 | Nucleotide and oligonucleotide prodrugs | SPRING BANK PHARMACEUTICALS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-8076303-B2 | Nucleotide and oligonucleotide prodrugs | SPRING BANK PHARMACEUTICALS, INC. (US) | 2011-12-13 | — | — | US | disclosed |
| US-20100145063-A1 | 2- thioethenyl substituted carbapenem derivatives | MARUYAMA TAKAHISA | 2010-06-10 | — | — | US | disclosed |
| US-7687490-B2 | 2-thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| EP-1941873-A1 | METALLO-BETA-LACTAMASE INHIBITOR | MEIJI SEIKA KAISHA LTD. (JP) | 2008-07-09 | — | — | EP | disclosed |
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | MEIJI SEIKA KAISHA, LTD. (JP) | 2008-04-17 | — | — | US | disclosed |
| EP-1870412-A1 | 2-THIOETHENYL CARBAPENEM DERIVATIVE | MEIJI SEIKA KAISHA LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
| US-20070149462-A1 | Nucleotide and oligonucleotide prodrugs | SPRING BANK PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149462-A1 | Nucleotide and oligonucleotide prodrugs | SPRING BANK PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090825-A1 | Metallo-beta-lactamase inhibitors | ME1, MGAM, GAA | TSHR 4198/4885TDP1 2860/4885MEN1 332/4885 |
| US-20100145063-A1 | 2- thioethenyl substituted carbapenem derivatives | MTAP, BLVRB, TPMT | TSHR 1626/4885TDP1 2900/4885MEN1 3301/4885 |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MTAP, BLVRB, BPGM | TSHR 1341/4885TDP1 3001/4885MEN1 2685/4885 |
| US-20070149462-A1 | Nucleotide and oligonucleotide prodrugs | TYMP, PNP, DUT | TSHR 4194/4885TDP1 593/4885MEN1 3192/4885 |
| US-20160060287-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | TYMP, PNP, DUT | TSHR 4194/4885TDP1 593/4885MEN1 3192/4885 |
| US-20140323554-A1 | NUCLEOTIDE AND OLIGONUCLEOTIDE PRODRUGS | TYMP, PNP, DUT | TSHR 4194/4885TDP1 593/4885MEN1 3192/4885 |
| US-20160151322-A1 | METALLO-B-LACTAMASE INHIBITORS | ME1, MGAM, MANBA | TSHR 4147/4885TDP1 3098/4885MEN1 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.